42.10
+0.24%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vimian Group
Its shares trade on Nasdaq Stockholm under the ticker VIMIAN.ST. It has been listed since 18 June 2021. In the fiscal year to 31 December 2025, it reported revenue of €425.0m and net income of €31.3m. At that date it held total assets of €1.11bn and shareholders' equity of €698.9m.
Vimian Group AB operates as an animal health company. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2021-06-18. The firm is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The firm invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 18 Jun 2021
- Employees
- 900
- Website
- vimian.com ↗
Leadership
Pay as last reported
- Mr. Magnus WelanderIndependent Chairman of the Board
- Mr. Carl-Johan BoudrieInterim Chief Executive Officer, Chief Financial Officer
- Mr. Magnus KjellbergChief Executive Officer, Nextmune
- Mr. Stefano SantarelliChief Executive Officer, Indical Bioscience
- Mr. Guy SpoerriChief Executive Officer, Movora
- Mr. Alireza TajbakhshChief Executive Officer, VetFamily
- Mr. Carl-Johan EhnGeneral Counsel
- Mr. Martin BengtsonHead of Mergers and Acquisition
- Mr. Theodor BonnierNon-Executive Director
- Mr. Gabriel FitzgeraldNon-Executive Director
- Ms. Pia MarionsIndependent Director
- Ms. Petra RumpfNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vimian Group AB has a strong presence in the animal health sector with 900 employees.
- The company operates as a parent company with a focus on improving animal health through science and technology.
- Vimian Group delivers solutions to veterinary professionals, labs, and pet parents globally.
Weaknesses
- The company's IPO was in 2021, indicating a relatively recent market entry.
- Vimian Group is a parent company with multiple subsidiaries, which may complicate management.
- The company's operations are limited to the animal health sector, potentially restricting diversification.
Opportunities
- The Group covers four rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services, and MedTech.
- Vimian provides individual businesses with access to networks, advisory services, infrastructure, and capital.
- Investing in innovation and new technologies can advance veterinary medicine and expand market reach.
Threats
- The company's reliance on the animal health sector may expose it to industry-specific risks.
- The firm's untrusted source description may lead to inaccurate public perception.
- As a parent company, Vimian Group faces challenges in aligning diverse subsidiary operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.